Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALPL | P05186 | 8/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038627 | 0.88 | ALK (0.47) | ALKLMNAALDH1A1L3MBTL1MEN1 | |
| SCHEMBL1039223 | 0.88 | MAPT (0.54) | POLBALKLMNASMN1; SMN2TP53 | |
| SCHEMBL1039345 | 0.86 | MAPT (0.47) | ALKLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1039346 | 0.85 | PIK3CA (0.46) | ALKLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1040988 | 0.84 | MAPT (0.56) | POLBALKLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1041142 | 0.84 | CCR2 (0.48) | POLBALKLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1037744 | 0.84 | MAPT (0.50) | POLBALKLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1036609 | 0.83 | LMNA (0.48) | POLBLMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1036556 | 0.81 | LMNA (0.49) | POLBALKLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14432669 | 0.80 | ALK (0.50) | ALKSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101547902-B | pyridine derivatives for treatment of metabolic disorders related with insulin resistance and hyperglycemia | PIRAMAL LIFE SCIENCES LTD | 2012-10-31 | — | — | CN | claimed |
| US-20110312970-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-12-22 | — | — | US | claimed |
| US-8030324-B2 | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | PIRAMAL LIFE SCIENCES LTD. (IN) | 2011-10-04 | — | — | US | claimed |
| EP-2094663-B1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-01-26 | — | — | EP | claimed |
| US-20100022554-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Enterprises Limited (IN) | 2010-01-28 | — | — | US | claimed |
| EP-2094663-A2 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | claimed |
| WO-2008035305-A2 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | claimed |
| US-8349862-B2 | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | PIRAMAL HEALTHCARE LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| CN-101547902-B | pyridine derivatives for treatment of metabolic disorders related with insulin resistance and hyperglycemia | PIRAMAL LIFE SCIENCES LTD | 2012-10-31 | — | — | CN | disclosed |
| US-20110312970-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-12-22 | — | — | US | disclosed |
| US-8030324-B2 | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | PIRAMAL LIFE SCIENCES LTD. (IN) | 2011-10-04 | — | — | US | disclosed |
| EP-2094663-B1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-01-26 | — | — | EP | disclosed |
| US-20100022554-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Enterprises Limited (IN) | 2010-01-28 | — | — | US | disclosed |
| EP-2094663-A2 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008035305-A2 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022554-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | GPR119, INSR, PDXK | POLB 3669/4885ALPL 1443/4885ALK 3054/4885 |
| US-20110312970-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | GPR119, INSR, PDXK | POLB 3669/4885ALPL 1443/4885ALK 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.